MDMA and Psilocybin: Clinical Case Studies
The webinar offers mental health specialists a chance to explore real case studies and gain insights into the clinical applications of MDMA and Psilocybin from experts.
About this webinar
Since 2014, Switzerland's Federal Office of Public Health has issued individual licenses for psychedelic treatment, including MDMA, LSD, and psilocybin, under an exemption article in the Swiss Narcotics Act. These licenses are granted based on therapeutic justifications for patients who have not responded adequately to other treatments, both pharmacological and psychotherapeutic. Unlike many other programs, these licenses are not restricted to specific diagnoses, allowing exploration of conditions with limited research. The licenses are initially granted for one year, with the possibility of extension to accommodate the therapeutic process. The psychedelic therapy typically spans 2-3 years, involving 5 to 7 psychedelic sessions within approximately 30 talk psychotherapy sessions. Furthermore, this webinar will discuss case studies based on the results observed in Switzerland.
Learning Outcomes
Understand Switzerland's regulatory framework for licensing psychedelic treatments and its therapeutic rationale.
Explore the diverse patient populations and conditions benefiting from psychedelic therapy in Switzerland, beyond traditional diagnostic boundaries.
Gain insights into the practical application and therapeutic process of psychedelic therapy through the analysis of Swiss case studies.
Peter Gasser is born in 1960, married, three children. He is a MD for psychiatry and psychotherapy, working in his own practice in Solothurn, Switzerland. He was trained in psychodynamic psychotherapy methods as well as in therapy with mind-altering substances, i.e. psycholytic or psychedelic therapy. He is a member of the Swiss Medical Society for Psycholytic Therapy since 1992 and its president since 1996. After 2007, he conducted two studies on LSD-assisted therapy in patients with anxiety due to life-threatening illness or as psychiatric anxiety disorder. Since 2014, he has held about 30 individual case treatment authorisations from the Swiss Health Authority within the Swiss limited use program of psychedelics. He worked with MDMA, LSD and Psilocybin.
Peter Oehen attended medical school at the University of Basel, Switzerland, and was board certified in psychiatry and psychotherapy in 1988. His psychotherapeutic training included Guided Affective Imagery Therapy, Systemic Couples and Family Therapy, and Psycholytic Therapy. Since his introduction to psychedelics during the registration period in Switzerland 1988-93, he has been dedicated to the therapeutic use of altered states of consciousness, especially those mediated by psychedelic substances. He was PI of a small phase II MDMA/PTSD study in 2013. He has been a member of the Swiss Medical Association for Psycholytic Therapy (SAePT) since 1987. Peter Oehen worked from 1988-2020 in private practice in Biberist/Switzerland. From 2014-2020 he was allowed to use LSD and MDMA in his private practice within the framework of the "Swiss limited medical use program" for psychedelic-assisted psychotherapy with MDMA and LSD in individual and group settings.
Webinar
When: Tuesday, 9 July 2024
Time: 7:00 pm
Cost: Free
By registering for this webinar, you consent to receiving communications from Medihuanna and our sponsors related to this event.